EMA Authorised: Pelmeg (pegfilgrastim) — Mundipharma Corporation (Ireland) Limited

View source ↗

Summary

EMA authorised Pelmeg, a pegfilgrastim biosimilar by Mundipharma, to reduce the duration of neutropenia and the risk of febrile neutropenia in cancer patients r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Chemotherapy-induced Neutropenia
• Neutropenia

Drugs mentioned

• Pelmeg (pegfilgrastim)

Snippet

Status: Authorised. MAH: Mundipharma Corporation (Ireland) Limited. Decision date: 17/03/2026